Literature DB >> 28689253

Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene.

Abhisheak Sharma1,2,3, Swati Jaiswal1,2, Mahendra Shukla1,2, Jawahar Lal4,5.   

Abstract

The study was intended to investigate the effect of concomitant administration of antimalarial drug (pyrimethamine or arteether) on pharmacokinetic and post coitus contraceptive efficacy of ormeloxifene in female Sprague-Dawley rats. A serial sampling technique coupled with LC-MS/MS detection was utilized for quantification of ormeloxifene in plasma samples collected from female rats treated with ormeloxifene only and ormeloxifene with pyrimethamine or arteether. Coitus-proven female rats were utilized to investigate the effect of pyrimethamine or arteether coadministration on contraceptive efficacy of ormeloxifene by investigating the presence or absence of implantations and status of corpora lutea on day 10 post coitum. None of the sperm-positive rats treated with ormeloxifene with or without coadministration of pyrimethamine or arteether showed any sign of pregnancy, confirming that concomitant administration of antimalarial drugs (pyrimethamine or arteether) did not affect the pharmacodynamic profile of ormeloxifene. Although there was no sign of pharmacodynamic interaction, the volume of distribution of ormeloxifene increased significantly on cotreatment with pyrimethamine. However, coadministration of arteether did not affect any of the pharmacokinetic parameters of ormeloxifene. The compiled results of preliminary study in female rats support that pyrimethamine or arteether can be prescribed with ormeloxifene.

Entities:  

Keywords:  Antimalarial; Centchroman; Contraceptive; Drug interaction; LC-MS/MS

Mesh:

Substances:

Year:  2017        PMID: 28689253     DOI: 10.1007/s00210-017-1401-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  On the pill.

Authors:  Ellen Friedrichs
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

2.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

Review 3.  Clinical pharmacokinetics and interaction of centchroman--a mini review.

Authors:  Jawahar Lal
Journal:  Contraception       Date:  2010-01-04       Impact factor: 3.375

Review 4.  Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders.

Authors:  M M Singh
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

Review 5.  Interactions between oral contraceptives and other drugs.

Authors:  A M Breckenridge; D J Back; M Orme
Journal:  Pharmacol Ther       Date:  1979       Impact factor: 12.310

6.  Protein binding and drug clearance.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Abhisheak Sharma; Swati Jaiswal; Mahendra Shukla; Mohd Yaseen Malik; Jawahar Lal
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-06-03       Impact factor: 3.205

8.  Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats.

Authors:  Vipul Kumar; Jawahar Lal; Man Mohan Singh; Ram Chandra Gupta
Journal:  Contraception       Date:  2006-04-27       Impact factor: 3.375

9.  Evaluation of interaction potential of certain concurrently administered drugs with pharmacological and pharmacokinetic profile of centchroman in rats.

Authors:  M Khurana; J Lal; M M Singh; J K Paliwal; V P Kamboj; R C Gupta
Journal:  Contraception       Date:  2002-07       Impact factor: 3.375

10.  Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.

Authors:  Kimberly K Scarsi; Kristin M Darin; Shadia Nakalema; David J Back; Pauline Byakika-Kibwika; Laura J Else; Sujan Dilly Penchala; Allan Buzibye; Susan E Cohn; Concepta Merry; Mohammed Lamorde
Journal:  Clin Infect Dis       Date:  2015-12-08       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.